FDA Authorizes Fluralaner for New World Screwworm in Dogs

The FDA has authorized fluralaner for emergency treatment of New World screwworm in dogs, according to dvm360. The authorization adds Bravecto to the flea and tick products available for this emergency-use purpose.

New option for infested dogs and puppies

Dvm360 reports that the authorization gives veterinarians another prescription option for dogs and puppies affected by New World screwworm. Fluralaner is the active ingredient referenced in the FDA authorization, while Bravecto is identified by dvm360 as the product involved.

The development centers on emergency treatment of infestations, rather than routine flea and tick use. For veterinary teams, the authorization places a familiar parasite-control category within the immediate context of New World screwworm response.

Commercial relevance for animal health teams

Veterinary sales professionals can note that dvm360 characterizes Bravecto as the latest flea and tick product authorized for emergency use against New World screwworm. Discussions with veterinary customers can remain focused on the authorized emergency-treatment context, the prescription status noted by dvm360, and the availability of another option for infested dogs and puppies.

As clinics evaluate parasite-management needs, the FDA action creates a timely regulatory update for teams supporting canine practices. The news also underscores how product conversations may shift when an established flea and tick product receives authorization connected to an emergency animal-health concern.

What the authorization signals

According to dvm360, the key outcome is an additional prescription option for veterinarians managing New World screwworm in dogs and puppies. Animal health professionals should distinguish this specific emergency-use authorization from broader product positioning and keep communications aligned with the FDA action described by the publisher.